^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PD-L1 overexpression

    i
    Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
    Entrez ID:
    29126
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Related tests:
    1d
    PD-1+CD8+ T cell infiltration complements PD-L1 to predict first-line chemo-immunotherapy outcomes in advanced ESCC. (PubMed, Biomark Res)
    Combined stratification identified the longest PFS in high PD-L1 expression and low PD-1+CD8+ T cell infiltration (8.8 months) and the shortest in low PD-L1 and high PD-1+CD8+ T cell infiltration (3.5 months), supporting PD-1+CD8+ T cell infiltration might as a complementary biomarker to PD-L1. For OS, intratumoral CD8+ T cell density (HR 0.896; p = 0.011), clinical stage (HR 1.570; p = 0.025), and BMI (HR 0.935; p = 0.015) were independent factors.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule)
    |
    PD-L1 expression • PD-L1 overexpression
    1d
    Neoadjuvant nivolumab plus chemotherapy in resectable NSCLC: A pharmacological outcome study. (PubMed, Pak J Pharm Sci)
    Neoadjuvant nivolumab combined with platinum-based chemotherapy demonstrates favorable pharmacological efficacy, manageable toxicity and biomarker-driven therapeutic response in resectable NSCLC under real-world clinical conditions. These findings support the role of personalized immunopharmacotherapy and reinforce the clinical relevance of biomarker-guided drug selection in modern pharmaceutical oncology.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    PD-L1 expression • KRAS mutation • PD-L1 overexpression
    |
    Opdivo (nivolumab)
    3d
    Integrated Molecular and Clinical Analysis of Thymic Epithelial Tumors. (PubMed, JCO Precis Oncol)
    Integrated profiling of TETs reveals distinct genomic, transcriptomic, and immune features across subtypes of TETs and identifies potentially actionable therapeutic targets that may inform future treatment strategies.
    Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • MTAP (Methylthioadenosine Phosphorylase) • MSLN (Mesothelin) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    PD-L1 expression • TP53 mutation • TMB-H • MSI-H/dMMR • PD-L1 overexpression • HER-2 overexpression • EGFR expression • TMB-L • CDKN2A deletion
    |
    MI Tumor Seek™
    3d
    Prognostic characterization of papillary thyroid carcinoma: Insights into the role of PD-L1 and mutational landscape in disease aggressiveness and outcome. (PubMed, Am J Clin Pathol)
    PD-L1 is a robust biomarker of aggressiveness in PTC. Integrating PD-L1 testing with molecular profiling can enhance postoperative risk stratification and guide personalized management.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • TERT (Telomerase Reverse Transcriptase)
    |
    PD-L1 overexpression • BRAF mutation
    5d
    NFE2L2-mutated urothelial carcinomas frequently show concomitant myxoid and squamous features and have high PD-L1 expression. (PubMed, Histopathology)
    These findings suggest that NFE2L2-mutated urothelial carcinomas frequently have concomitant squamous and myxoid features, aggressive behaviour and high PD-L1 expression. Recognition of the NFE2L2-mutated urothelial carcinomas may have diagnostic and prognostic utility, particularly with immunotherapy and possible targeted therapy against the NRF2 signalling pathway. Further investigation with larger cohorts is warranted to expand the data surrounding NFE2L2 mutations in urothelial carcinoma.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
    |
    PD-L1 expression • PD-L1 overexpression • NFE2L2 mutation
    7d
    Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker. (PubMed, Target Oncol)
    Adjuvant pembrolizumab exhibited feasible efficacy and manageable safety profiles for high-risk RCC in a real-world population. Further studies with longer follow-up periods and larger sample sizes are needed to confirm overall survival benefit, long-term toxicity, and the potential role of PD-L1 as a prognostic biomarker.
    Journal • Real-world evidence • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Keytruda (pembrolizumab)
    7d
    PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis. (PubMed, JAMA Oncol)
    In this meta-analysis of phase 3 RCTs, chemoimmunotherapy was associated with significantly improved OS and PFS compared with PD-(L)1 inhibitor monotherapy in patients with advanced NSCLC and high PD-L1 expression. Prospective trials are needed to confirm these findings.
    Clinical • Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1)
    |
    PD-L1 expression • PD-L1 overexpression
    8d
    Clinical Value of the Systemic Immune Inflammation Index and PD-L1 Expression in Advanced NSCLC Treated with Pembrolizumab: Real-World Preliminary Study. (PubMed, Oncol Res)
    Furthermore, patients with a combination of low SII and high PD-L1 expression demonstrated the most favorable survival outcomes. Although further prospective and multicenter studies are needed to validate the generalizability of our findings, the clinical implication is that the use of pretreatment SII and/or PD-L1 expression values may predict therapeutic outcomes and assist in optimizing individualized treatment strategies for patients with advanced NSCLC.
    Journal • Real-world evidence • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Keytruda (pembrolizumab)
    8d
    Renal Pelvis Squamous Cell Carcinoma Arising in the Setting of Long-Standing Nephrolithiasis: Clinicopathologic and Molecular Insights. (PubMed, Int J Surg Pathol)
    Molecular analysis revealed TP53 alterations in both tumors and a TERT promoter mutation (C228T) in one tumor, which was associated with early distant metastases. These findings support the concept that renal pelvis SCC represents a biologically distinct, inflammation-driven carcinoma with adverse prognosis, limited response to conventional therapy, and potential relevance of immune checkpoint inhibition.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TERT (Telomerase Reverse Transcriptase) • TP63 (Tumor protein 63) • KRT5 (Keratin 5)
    |
    PD-L1 expression • PD-L1 overexpression
    8d
    SWOG S1609: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov)
    P2, N=798, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: May 2027 --> May 2026
    Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    PD-L1 overexpression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
    13d
    Impact of Immune Checkpoint Inhibitor-Combined Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer With Brain Metastases. (PubMed, Clin Lung Cancer)
    Chemo-ICI was effective and safe in NSCLC patients with CNS metastases, including corticosteroid-treated symptomatic patients. High PD-L1 expression and early brain radiotherapy were favorable prognostic factors.
    Review • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 overexpression
    13d
    Molecular Heterogeneity and Individualized Therapeutic Targets of Oral Squamous Cell Carcinoma: A Study of PI3K/AKT/mTOR Pathway and PD-L1 Expression. (PubMed, J Stomatol Oral Maxillofac Surg)
    OSCC tumors frequently activate this pathway, which tracks with aggressive behavior. The dual association of p-AKT positivity with poor survival and PD-L1 overexpression suggests its potential utility in stratifying patients for regimens combining targeted therapy with immune checkpoint blockade.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 overexpression